Literature DB >> 8989342

Analgesia for dying infants whose life support is withdrawn or withheld.

J C Partridge1, S N Wall.   

Abstract

OBJECTIVE: To determine the frequency of opiate analgesia administration to infants when life support is discontinued and to determine whether infant characteristics, such as birth weight and diagnosis, or the physician's reasons for discontinuing life support influence either the decision to provide opioid agents or the dosages administered.
METHODS: We reviewed all 165 deaths in a 3-year period at a university-based level III intensive care nursery. Of the 121 deaths attributable to withdrawal or withholding of mechanical ventilation and/or extracorporeal membrane oxygenation, we ascertained whether opioid analgesics (morphine sulfate [MS] or fentanyl) were administered either concurrent with or after life-support withdrawal and at what doses. We examined whether these end-of-life practices varied according to birth weight, diagnoses, and the reasons documented by the neonatologist for discontinuing life support.
RESULTS: Opioid analgesia was provided to 84% of infants as their life support was either withheld or withdrawn. Infants with necrotizing enterocolitis and major anomalies or chromosomal disorders were more likely to be given opiates than infants with other diagnoses. Birth weight was not different for infants who received opiates compared with those who were not given opiates. Opioid analgesia was provided to all 18 infants for whom physicians documented the patients' suffering as a reason to discontinue life support. Sixty-four percent of infants who received opiates were given doses in the usual pharmacologic range of 0.1 to 0.2 mg/kg MS. Of the 36 infants given more than 0.2 mg/kg MS, all but 2 were receiving ongoing treatment with opioid agents.
CONCLUSIONS: In most cases of withholding or withdrawal of life support in critically ill infants, neonatologists provided opioid analgesia to these infants at the end of life, despite the potential respiratory depression of opioid agents in infants whose respiratory support is discontinued.

Entities:  

Keywords:  Death and Euthanasia; Empirical Approach

Mesh:

Substances:

Year:  1997        PMID: 8989342     DOI: 10.1542/peds.99.1.76

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  The use of drugs with a life-shortening effect in end-of-life care in neonates and infants.

Authors:  Veerle Provoost; Filip Cools; Johan Bilsen; José Ramet; Peter Deconinck; Robert Vander Stichele; Anne Vande Velde; Inge Van Herreweghe; Freddy Mortier; Yvan Vandenplas; Luc Deliens
Journal:  Intensive Care Med       Date:  2005-11-15       Impact factor: 17.440

2.  Death in the neonatal intensive care unit: changing patterns of end of life care over two decades.

Authors:  D J Wilkinson; J J Fitzsimons; P A Dargaville; N T Campbell; P M Loughnan; P N McDougall; J F Mills
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-07       Impact factor: 5.747

Review 3.  Ensuring pain relief for children at the end of life.

Authors:  Marie-Claude Grégoire; Gerri Frager
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

4.  Decision making and modes of death in a tertiary neonatal unit.

Authors:  R Roy; N Aladangady; K Costeloe; V Larcher
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-11       Impact factor: 5.747

5.  Relationship of neonatologists' end-of-life decisions to their personal fear of death.

Authors:  Peter Barr
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-02-06       Impact factor: 5.747

6.  Sedatives and Analgesics Given to Infants in Neonatal Intensive Care Units at the End of Life.

Authors:  Kanecia O Zimmerman; Christoph P Hornik; Lawrence Ku; Kevin Watt; Matthew M Laughon; Margarita Bidegain; Reese H Clark; P Brian Smith
Journal:  J Pediatr       Date:  2015-05-23       Impact factor: 6.314

7.  Impact of a palliative care program on end-of-life care in a neonatal intensive care unit.

Authors:  N Younge; P B Smith; R N Goldberg; D H Brandon; C Simmons; C M Cotten; M Bidegain
Journal:  J Perinatol       Date:  2014-10-23       Impact factor: 3.225

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.